Shopping Cart
- Remove All
Your shopping cart is currently empty
Amcasertib (BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways by targeting stemness kinases.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $50 | In Stock | |
| 5 mg | $118 | In Stock | |
| 10 mg | $195 | In Stock | |
| 25 mg | $413 | In Stock | |
| 50 mg | $618 | In Stock | |
| 100 mg | $879 | In Stock | |
| 500 mg | $1,790 | In Stock |
| Description | Amcasertib (BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways by targeting stemness kinases. |
| Kinase Assay | Standard incubation mixtures (final volume of 0.20 mL) containe recombinant P450 (0.010 μM) in 50 mM potassium phosphate bu?er (pH 7.4) containing an NADPH-generating system (0.5 mm NADP+, 5 mM glucose 6-phosphate, 0.5 unit glucose 6-phosphate dehydrogenase/mL) and substrates (1±100 lM). For determination of CYP1A2, CYP2B6, CYP2E1 and CYP3A4 activities, 100 mM potassium phosphate buffer (pH 7.4) is used. When human liver microsomes are used as the enzyme source, 500, 25, 100 and 25 pmol totalP450 per mL are used for paclitaxel 6a-hydroxylation, S-warfarin 7-hydroxylation,S-mephenytoin 4′-hydroxylation and testosterone 6b-hydroxylation respectively. |
| Synonyms | BBI503 |
| Molecular Weight | 539.69 |
| Formula | C31H33N5O2S |
| Cas No. | 1129403-56-0 |
| Smiles | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C |
| Relative Density. | 1.246 g/cm3 (Predicted) |
| Color | Orange |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 5.4 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.85 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.